LENZ Therapeutics Inc
LENZ14.220USD
+0.250+1.79%
終値 02/06, 16:00（ET）15分遅れの株価
406.53M時価総額
損失額直近12ヶ月PER
詳細情報 LENZ Therapeutics Inc 企業名
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Incの企業情報
企業コードLENZ
会社名LENZ Therapeutics Inc
上場日Jun 25, 2021
最高経営責任者「CEO」Schimmelpennink (Evert)
従業員数42
証券種類Ordinary Share
決算期末Jun 25
本社所在地- -
都市- -
証券取引所NASDAQ OMX - NASDAQ BASIC
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コードLENZ
上場日Jun 25, 2021
最高経営責任者「CEO」Schimmelpennink (Evert)
LENZ Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Feb 1
更新時刻: Sun, Feb 1
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
他の
55.35%
株主統計
株主統計
比率
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
他の
55.35%
種類
株主統計
比率
Venture Capital
34.63%
Investment Advisor
30.64%
Hedge Fund
23.82%
Investment Advisor/Hedge Fund
16.91%
Individual Investor
2.52%
Research Firm
2.00%
Pension Fund
0.23%
Bank and Trust
0.13%
Insurance Company
0.02%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
308
33.89M
108.31%
+1.02M
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
詳細を見る
State Street SPDR S&P Pharmaceuticals ETF
比率1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.04%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.27%
iShares U.S. Pharmaceuticals ETF
比率0.22%
ProShares Ultra Nasdaq Biotechnology
比率0.11%
iShares Micro-Cap ETF
比率0.09%
Invesco Nasdaq Biotechnology ETF
比率0.08%
iShares Biotechnology ETF
比率0.06%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
日付
配当落ち日
種類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
